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ABSTRACT
Photodynamic therapy (PDT) showed promising efficacy for local failure after 
chemoradiotherapy (CRT) for esophageal cancer. However, PDT required long sun 
shade period. This study aimed to evaluate the safety and efficacy of PDT using 
second generation photosensitizer, talaporfin sodium for local failure after CRT. 
This was the multi-institutional non-randomized phase II study. Patients with 
histologically proven local failure limited within the muscularis propria after 50Gy 
or more radiotherapy (RT) for esophageal cancer were eligible. We set the primary 
endpoint as local complete response (L-CR) per patients. And, secondary endpoints 
were confirmed L-CR, local progression free survival (L-PFS), progression free 
survival (PFS), overall survival (OS), L-CR per lesions (Lesion L-CR), and confirmed 
Lesion L-CR. The PDT procedure commenced with intravenous administration of a 
40 mg/m2 dose of talaporfin sodium followed by diode laser irradiation at a 664 
nm wavelength. 26 eligible patients were enrolled and all were treated with PDT. 
Twenty three patients with 25 lesions were assessed L-CR after PDT; the L-CR 
rate per patients was 88.5% (95% CI: 69.8%-97.6%). No skin phototoxicity was 
observed, and no grade 3 or worse non-hematological toxicities related to PDT 
were observed. PDT using talaporfin sodium and a diode laser is a safe and curative 





Esophageal cancer is the eighth most common 
cancer worldwide and sixth leading cause of cancer-related 
death [1]. While neoadjuvant chemoradiotherapy (CRT) 
or chemotherapy followed by surgery is the standard 
treatment for resectable esophageal cancer, definitive CRT 
is still one of the curative treatment options for the patients 
with un-resectable tumors and those with unsuitable or 
refusal for surgery. However, locoregional failure after 
definitive CRT has been the major problem, and its rate 
was as great as 50-55% [2, 3]. For those patients, salvage 
surgery is indicated, however, it is associated with a 
high complication rate (50-77%) and high mortality rate 
(approximately 15%) [4–7].
Among the patients with locoregional failure after 
definitive CRT, some patients don’t have distant or lymph 
node metastasis. Such patients have the potential to be 
cured by local treatment such as endoscopic resection 
(ER) [8, 9], or photodynamic therapy (PDT) [10–12]. 
However, ER has limitations for its indication restricted 
to only mucosal residue due to technical difficulties. PDT 
is relatively easy to control the technical quality and its 
effect is expected to deeper residue to submucosal layer. 
However, PDT using the first generation photosensitizer, 
porfimer sodium, and excimer dye laser has several 
problems such as a high occurrence of skin phototoxicity, 
a long sun shade period requirement as approximately 6 
weeks, and the necessity of an expensive and large laser 
system for excitation.
The second generation photosensitizer, talaporfin 
sodium (ME2906, Meiji Seika Pharma Co., Ltd., Tokyo, 
Japan) is rapidly cleared from the skin and require shorter 
sun shade period (within 2 weeks) [13, 14]. Furthermore, 
the depth of effect is expected to deeper layer to 
muscularis propria because the excited wavelength of 
diode laser (PNL6405EPG, Panasonic Healthcare Co., 
Ltd., Ehime, Japan) is longer than excimer dye laser (630 
nm). Therefore, the second generation PDT is expected 
as salvage treatment for local failure after CRT for 
esophageal cancer. After completion of preclinical and 
phase I study [15–17], we conducted a phase II study to 
evaluate the efficacy and safety of PDT using talaporfin 
sodium and a diode laser for local failure after CRT or 
radiotherapy alone (RT).
RESULTS
Between November 2012 and December 2013, 26 
eligible patients were enrolled and all completed PDT and 
were included full analysis set. Baseline characteristics 
of the patients and lesions are shown in Table 1. Twenty 
one patients were treated with CRT, and the remaining 5 
patients were treated with RT. Solitary failure lesions were 
found in24 of 26 patients, while the other 2 patients had 2 
lesions each. All lesions were confirmed as squamous cell 
carcinoma, and T1b was in 21, and T2 was in 7 lesions, 
respectively.
Treatment flow and efficacy
The study flow is summarized in Figure 1. Sixteen 
patients received additional laser irradiation. Median laser 
exposure dose at day 1 was 300J (range: 200-800), and 
median additional laser exposure dose at day2 was 100J 
(range: 100-300), therefore the median total laser exposure 
dose was 400J (range: 200-900). The efficacy of PDT is 
summarized in Table 2. Twenty three patients with 25 
lesions were assessed local complete response (L-CR) 
after PDT (L-CR rate: 88.5%, 95% CI: 69.8%-97.6%), 
and all patients achieve confirmed L-CR (cL-CR)(Figure 
2). The Bayesian posterior probability that the L-CR 
rate is greater than threshold (15%) was almost 100%. 
The best response of the other 3 patients was nonCRnon 
progressive disease (PD), and 2 of them developed L-PD 
thereafter. All L-CR cases achieved L-CR within 20 weeks 
after PDT. The L-CR rate and cL-CR rate per lesion was 
89.3% (95% CI: 71.8%-97.7%). Moreover, L-CR rate 
of T1 failure lesions was 100% (19/19, 95% CI: 82.4%-
100%), whereas the L-CR rate of T2 failure lesions was 
57.1% (4/7, 95% CI:18.4%-90.1%).
Safety
The hematological and non-hematological 
toxicities related to PDT in this study are summarized 
in Table 3. No skin phototoxicity was observed, and 18 
(69.2%) patients were evaluated as non-reactionary with 
a skin photosensitivity test a week after administration 
of talaporfin sodium, and all remaining patients were 
evaluated as non-reactionary within 2 weeks after PDT. 
Common toxicities related to PDT were esophageal pain 
in 14 (53.8%), fever in 8 (30.8%). There was no case of 
treatment related death.
Survival
The survival curves are shown in Figure 3. The 
median follow up period was 8.4 months (range: 1.2-17), 
and no patients died from esophageal cancer progression. 
Two non-CRnonPD patients with PDT developed 
progression thereafter, and 1 CR patient developed local 
recurrence approximately 14 months after PDT. The other 
2 patients died due to pneumonia at 81 days, and 156 days 
after PDT. Therefore, 5 events were confirmed for the 
L-PFS curve at present, and the median L-PFS was 428 
days (Figure 3-3a). Total 10 events related to PFS were 
observed in this study. Three patients developed lymph 
node or distant metastasis at 91, 115, and 119 days after 
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Table 1: Baseline characteristics of 26 patients and 28 lesions




















  cisplatin and 5FU 11
  nedaplatin and 5FU 3
  others 7
 Radiotherapy alone 5
Total dose of radiotherapy (Gy)
 ≥50, <60 7
 60 17
 >60, ≤70 2
Number of failure lesion
 1 24
 2 2
T stage at failure
 T1 21
 T2 7
Failure pattern of lesions
 recurrence after achieving CR 22
 residual lesion just after CRT 6
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enrollment, a patient developed intramural metastasis of 
esophagus at 85 days after PDT and treated with PDT 
using porfimer sodium. Another superficial esophageal 
cancer was detected and cured with ER in the other 3 
patients. And, 2 patients developed local progression at 
87 days and 428 days after PDT, and another patient died 
with pneumonia at 81 days after PDT same as above. No 
patients received salvage surgery for recurrence after PDT. 
Therefore the median PFS was 428 days (Figure 3-3b). 
As for OS, only 2 events described earlier were observed, 
and thus the median survival is undefined for this follow 
up period (Figure 3c).
DISCUSSION
We herein demonstrated that salvage PDT with 
talaporfin sodium showed an excellent high local CR 
rate (88.5%, 95%CI: 69.8%-97.6%) with acceptable 
safety after failure for definitive CRT. This result is 
clinically very important because the patients with only 
local failure at the primary site without metastasis after 
CRT have a potential to get cured without high-risk 
salvage surgery.
In this study, we adopted the CR rate rather 
than the response rate as a primary endpoint. As PDT 
is a local treatment, it can provide treatment effect 
only for the local site. In our previous study using 
porfimer sodium, patients who could achieve CR at 
the primary site survived longer [18]. Therefore, we 
believe that local control, especially the CR rate at the 
primary site, has clinical significance in salvage PDT 
strategy. Regarding the outcomes of CRT, the survival 
benefits of achieving CR were also clarified [19, 20]. 
In contrast, the survival of the patients who could not 
achieve CR was quite dismal, and most died within 1 
year [20]. Furthermore, patients who could not achieve 
CR with CRT developed progressive disease at a 
median timeframe of approximately 1 month [21], and 
that might lead to dysphagia due to obstruction with 
progressive primary disease. Therefore, achieving CR at 
primary site is clinically important not only for survival 
but also for patients’ quality of life.
Figure 1: The flow of study. 26 eligible patients were enrolled and all completed the intravenous administration of talaporfin sodium 
followed by diode laser irradiation and were included full analysis set. While 16 patients received additional laser irradiation, the remaining 
10 patients did not. 23 patients were assessed local complete response (L-CR), and the other 3 patients could not achieve L-CR after PDT.
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As for safety, the toxicity of PDT using talaporfin 
sodium and the laser was quite mild. The most severe 
toxicities related to PDT are esophageal perforation 
at the laser irradiated site. In our previous study of 
PDT using porfimer sodium, we experienced one 
treatment death due to gastrointestinal hemorrhage 
that might be caused by an esophageal-aortic fistula 
at the laser irradiated site [9]. Therefore, we excluded 
lesions that potentially involved the aorta before CRT, 
and there were no cases of perforation or treatment 
related death in present study. While in our prior 
study of PDT using porfimer sodium, we experienced 
32% skin phototoxicity with at least a month of sun 
shade period after administration of porfimer sodium 
[9]. In the present study, there were no cases of skin 
phototoxicity, even with 2 weeks sun shade period after 
administration of talaporfin sodium, and this might be 
one of the greatest strengths of this new generation 
photosensitizer.
There are several limitations in this study. The 
study was a single arm trial and did not compare the 
efficacy to the standard treatment. However, at this 
moment, there is no established standard treatment for 
local failure after CRT for patients with esophageal 
cancer. Furthermore, it might be quite difficult to carry 
out a randomized trial of PDT versus salvage surgery 
because of the difference of invasiveness. A randomized 
trial of PDT versus systemic chemotherapy is also 
Figure 2: A representative case that was able to achieve CR with PDT. a. a protruded local failure was present at the anterior 
wall of middle esophagus, and the estimated depth of the lesion was deep submucosal layer. b. After administration of talaporfin sodium, 
diode laser was exposed to the lesion. c. a week after PDT, ischemic change of mucosa was present at laser irradiated site. d. two months 
after PDT, post-PDT ulcer was disappear and scar formation was confirmed and biopsy was negative of cancer cells, therefore complete 
response was achieved with PDT.
Table 2: Best response after PDT
n L-CR nonCRnonPD L-PD NE CR rate 95%CI
26 patients 23 3 0 0 88.5% 69.8%-97.6%
28 lesions 25 3 0 0 89.3% 71.8%-97.7%
T1b lesions (21) 21 0 0 0 100% 83.9%-100%
T2 lesions (7) 4 3 0 0 57.1% 18.4%-90.1%
PDT: photodynamic therapy, L-CR: local complete response, L-PD: local progressive disease
NE: not evaluable, CI: confidence interval 
All patients and lesions with L-CR could also achieve confirmed CR.
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Figure 3: The survival curves in this study. a. Local progression free survival (L-PFS) curve; 5 events were observed during follow 
up. b. PFS curve; 10 events were observed during follow up. c. Overall survival curve; 2 events were observed during follow up.




1 2 3 4
Esophageal pain 13 1 0 0 14 (53.8%)
Dysphagia 1 1 0 0 2 (7.7%)
Esophageal stricture 2 0 0 0 2 (7.7%)
Laryngeal pain 1 0 0 0 1 (3.8%)
fever 7 1 0 0 8 (30.8%)
CRP increase 20 1 0 0 21 (80.8%)
Hypoalbuminemia 7 2 0 0 9 (34.6%)
AST increase 5 0 0 0 5 (19.2%)
ALT increase 5 0 0 0 5 (19.2%)
γ-GTP increase 3 0 0 0 3 (11.5%)
Lymphopenia 1 4 2 0 7 (26.9%)
Neutrophil count increase 3 0 0 0 3 (11.5%)
Total bilirubin increase 2 0 0 0 2 (7.7%)
Skin phototoxicity 0 0 0 0 0 (0%)
PDT: photodynamic therapy, CRP: C reactive protein, AST: aspartate aminotransferase
ALT: alanine aminotransferase, GTP: glutamyltranspeptidase
Figure 4: Illustration of PDT procedure.
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difficult because achievement of CR with systemic 
chemotherapy is quite difficult [22–26]. Taken all 
together, the high L-CR rate (88.5%) at the primary site 
of this new generation PDT for local failure after CRT 
should be considered of value as a treatment option. The 
follow up period of this study is insufficient. One-year 
OS of the patients in this study was 91.4% (95%CI: 
69.7%-97.8%). Therefore, short-term survival benefit of 
salvage PDT could be expected. Further follow up study 
with same subjects is now ongoing to confirm the long 
term survival benefit.
In conclusion, PDT using talaporfin sodium and 
a diode laser is a safe and potentially curative salvage 




This study was an investigator initiated multi-
institutional non-randomized open label phase II study. 
The study complied with the Good Clinical Practice 
Guideline for drugs and medical devices, and the 2008 
Declaration for Helsinki. The study protocol was approved 
by the institutional review board of all 7 participating 
hospitals. The study was registered with the University 
Hospital Medical Information Network Clinical Trials 
Registry (UMIN000009184).
Eligibility
The eligibility criteria were as follows: 1) local 
failure after CRT or RT (≥50Gy); 2) one week or longer 
from the last treatment for esophageal cancer, and any 
previous treatment is acceptable, except for PDT with 
talaporfin sodium or porfimer sodium; 3) histologically 
proven local failure, and either not candidates for salvage 
surgery or having a physical status that would make the 
surgery intolerable; 4) salvage ER not indicated due to 
incurability; 5) no invasion to the cervical esophagus; 
6) lesions limited to within the muscularis propria; 7) 
longitudinal lesion length of 3 cm or shorter and 1/2 the 
circumference of the lumen or less; 8) no more than 2 
lesions; 9) age ≥ 20 years old; 10) Eastern Cooperative 
Oncology Group performance status (ECOG-PS): 0-2; 11) 
adequate organ functions (white blood cell counts ≥2000 
/mm3, hemoglobin >8.0g/dL, platelet count ≥75000/
mm3, serum total bilirubin level ≤3.0 mg/dL, both alanine 
transferase and aspartate aminotransferase <100IU/L), 
12) provision of written informed consent. The exclusion 
criteria were as follows: 1) distant organ or lymph node 
metastasis that required systemic chemotherapy; 2) other 
active cancers, except for early cancers that are expected 
to be cured with local treatment such as ER, or cancers that 
do not require systemic treatment such as chemotherapy; 
3) significant cardiovascular diseases (uncontrolled 
hypertension, myocardial infarction, unstable angina, 
congestive heart failure), uncontrolled diabetes mellitus, 
severe liver cirrhosis, severe renal disorder; 4) systemic 
infection requiring antibiotics; 5) inability to comply 
the sun shade restrictions; 6) additional PDT just after 
salvage ER for local failure; 7) baseline lesions before 
CRT that were judged to involve the aorta; 8) porphyria, 
9) preexisting condition of sun photosensitivity; 10) 
previous treatment with PDT using porfimer sodium or 
talaporfin sodium; 11) for women, pregnancy or lactation, 
or unwillingness to use contraception; 12) severe bleeding 
or shock status; 13) bleeding tendency; 14) current 
participation or prior participation within 3 months in 
other clinical trials for unapproved and off-label drugs 
or medical devices; and 15) patients who judged by the 
investigator that enrollment was inappropriate.
Staging
Clinical stage was determined according to the 
TNM classification of the International Union Against 
Cancer 7th edition [27] and the Japanese Classification 
of Esophageal Cancer, 10th edition, revised version [28]. 
Clinical T stage was evaluated by endoscopy, endoscopic 
ultrasound (EUS), and computed tomography (CT) of the 
chest. Clinical N and M stages were evaluated by EUS and 
CT of the neck, chest and abdomen.
Procedure
The PDT procedure commenced with intravenous 
administration of 40 mg/m2 dose of talaporfin sodium 
followed by laser irradiation at a 664 nm wavelength 
after 4 to 6 hours after administration (Figure 4). The 
diode laser was delivered via frontal light distributor 
through the operative channel of endoscope. The plastic 
attachment was fitted in front of the scope to keep the 
distance between the tip of the scope and lesion. The 
fluence of diode laser was set at 100J/cm2 with a fluence 
rate of 150 mW/cm2. If the lesions were larger than 1 
cm2, multiple treatment fields were overlapped to cover 
the whole lesion. Endoscopic observation was mandatory 
at the next day, and if an obvious residual tumor was 
founded, additional laser irradiation was recommended. 
“Obvious residual tumor” refers to 1) the presence of a 
residual submucosal tumor-like protruded component, 
2) the presence of neoplastic mucosa or ulcer, and 3) the 
absence of edematous mucosa with redness or dark blue 
discoloration due to incomplete irradiation.
Follow up and evaluation
All patients were instructed to avoid direct sun 
exposure, and to stay in a room maintained at 500 lux 
or less for 2 weeks after PDT. A skin photosensitivity 
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test was performed every week after administration of 
talaporfin sodium, and discharge was allowed at day 
15 if the skin photosensitivity and other adverse events 
related with PDT disappeared. Patients were assessed with 
physical examinations, measurements of hematological 
and biochemical variables in the blood, chest radiograph 
studies, and endoscopic observation at least once a week 
until 28 days after PDT. Adverse events and toxicity were 
evaluated and graded according to Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. [29]
Efficacy
Clinical effect at the laser irradiated site was made 
by endoscopic examination with biopsy at day 22 and 29 
after PDT, and every 2 weeks during the second month, 
and every month thereafter for 6 months after PDT. The 
local efficacy was classified with endoscopic evaluation 
as L-CR, local progressive disease (L-PD), local 
nonCRnonPD (L-nonCR/nonPD), and not evaluable (NE) 
at each evaluation. The criteria of L-CR was as follows; 
1) no residual tumor was observed, 2) disappearance of 
post-PDT ulcer and scar formation was confirmed, and 
3) histologically disappearance of cancer cells. cL-CR 
was defined as 4 weeks or longer continuation of L-CR 
status. Endoscopic re-evaluation was performed by a 
central evaluation committee consisting of 3 experienced 
endoscopists who were independent to this study. The 
final efficacy outcome was determined by this committee. 
Conversely, the criteria of L-PD were as follows: 1) 
definitive progression compared with the lesion before 
enrollment, or 2) recurrence after achieving L-CR with 
PDT. And, when neither L-CR nor L-PD criteria were 
not met, lesions were classified as L-nonCR/nonPD. 
Furthermore, when endoscopic examination and tissue 
diagnosis by biopsy cannot be performed for some reason 
or when the lesion cannot be classified as L-CR, L-PD, 
or L-nonCR/nonPD, lesions were classified as NE. CT 
of the neck, chest and abdomen was performed every 3 
months after PDT. Lymph node metastasis was clinically 
diagnosed if the lymph node was visible and larger than 
10 mm.
Endpoints
The proportion of subjects whose best effect in the 
overall local therapeutic efficacy is L-CR is referred to 
as the L-CR rate per patients. And L-CR rate per patients 
was the primary endpoint of this study. And the proportion 
of lesions in which the best effect in the lesion local 
therapeutic efficacy is L-CR is referred to as the L-CR rate 
per lesion, and L-CR rate per lesion and confirmed L-CR 
rate per lesion were the secondary endpoints. And other 
secondary endpoints were local progression free survival 
(L-PFS), progression free survival (PFS), overall survival 
(OS).
Statistics
The threshold L-CR has been set to 15% for T1 
and T2 patients because the clinical significance would 
be limited unless the L-CR rate is confirmed to be more 
than this threshold. The expected L-CR rates for T1 and 
T2 patients have been set to 75% and 40%, respectively. 
A required sample size of 25 patients is calculated using 
Bayesian approach based on prior predictive distributions 
in single arm study [30], in which the uncertainty in T1:T2 
ratio in enrolled patients is also taken in to account by 
prior beta distribution with mode of 0.69 (9/13). However, 
ranges less than 0.24 and greater than 0.76 are truncated 
here, given that at least some T1 and T2 patients will 
be enrolled in this clinical trial. Treatment efficacious 
is declared if the Bayesian posterior probability that the 
L-CR is greater than the threshold value of 15% exceeds λ 
= 97.5%. Under the abovementioned settings, this sample 
size retains a one-sided alpha of 2.5% and power of 90% 
also in a frequentist analysis and interpretation, that is, 
this trial is designed to assure valid analyses in either 
traditional frequentist or Bayesian approaches. L-PFS 
was measured from the date of enrollment to the first 
date of confirmation of L-PD or death from any cause. 
If any events were not observed, the period was censored 
at the date of last endoscopic evaluation. And, PFS was 
measured from the date of enrollment to the first date of 
confirmation of L-PD or new metastasis or progression in 
a lymph node or a distal organ, or death from any cause. 
If any events were not observed, the period was censored 
at the date of last imaging test evaluation or physical 
examination. And, OS was measured from the date of 
enrollment to death from any cause. If any event was not 
observed, the period was censored at the date of last day 
on which the patient's survival has been confirmed. All 
authors had access to the study data and had reviewed and 
approved the final manuscript.
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